Is Titan Biotech overvalued or undervalued?

As of 7 July 2025, Titan Biotech's valuation grade has moved from very expensive to expensive, indicating a slight improvement in its perceived value. The company is currently considered overvalued. Key ratios include a PE ratio of 17.49, an EV to EBITDA of 14.71, and a Price to Book Value of 2.46, which suggest that the stock is trading at a premium compared to its earnings and assets.
In comparison to its peers, Titan Biotech's PE ratio is significantly lower than that of Solar Industries, which stands at 125.24, while Godrej Industries offers a more attractive PE of 40.15. This disparity highlights Titan's overvaluation in the context of its industry. Additionally, despite a recent strong performance with a 12.87% return over the past week, the year-to-date return of -37.77% reflects underlying challenges that may not justify its current price level.